San Diego, California–(Newsfile Corp. – November 2, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“ Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug (“IND“) application to the U.S. Food and Drug Administration (“FDA“) to evaluate its…


Previous articlePT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure
Next articleBraxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial